| 18F-FDG PET/CT evaluation of patients with ovarian carcinoma. | |
| | |
MedLine Citation:
|
PMID: 18987524 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The role of F-FDG PET has been studied in ovarian carcinoma, but its sensitivity and specificity calculations are based on dedicated PET acquisition, not PET/CT in the majority of the published studies. Therefore, we were prompted to review our experience with PET/CT in the management of patients with ovarian carcinoma. MATERIALS AND METHODS: This is a retrospective study of 43 women with ovarian carcinoma, 27-80 years old (average: 53.9+/-7.8), who had whole-body PET/CT at our institution from 1 January 2003 to 31 August 2006. We reviewed the patients' outcomes from medical records and compared them to the interpretation of the PET/CT scans. Sensitivity and specificity were calculated using a 2 x 2 table with pathology results (79.1% of the patients) or clinical follow-up (20.9% of the cases) as the 'gold standard'. Confidence interval (CI) estimations were performed using the Wilson score method. RESULTS: All patients had advanced stage ovarian cancer and the study was requested for re-staging. A total of 60 scans were performed: 30 patients had one scan, nine patients had two scans and four patients had three scans. The administered doses of F-FDG ranged from 381.1 to 769.6 MBq (average: 569.8+/-73.3). PET/CT had a sensitivity of 88.4% (95% CI: 75.1-95.4) and a specificity of 88.2% (95% CI: 64.4-97.9) for detection of ovarian cancer. The SUV max of the detected lesions ranged from 3 to 27 (average: 9.4+/-5.9). The CA-125 tumor marker ranged from 3 to 935 kU/ml (average: 265.2) in patients with positive scans and 4-139 kU/ml (average: 17.1) in patients with negative scans. This difference was statistically significant (P value: 0.0242). CONCLUSION: This study confirms the good results of F-FDG PET/CT for identification of residual/recurrent ovarian cancer, as well as for distant metastases localization. PET/CT should be an integral part in evaluation of patients with high-risk ovarian cancer or rising values of tumor markers (CA-125), prior to selection of the most appropriate therapy. |
| | |
Authors:
|
Andrei H Iagaru; Erik S Mittra; Iain Ross McDougall; Andrew Quon; Sanjiv Sam Gambhir |
Related Documents
:
|
14516534 - Fdg-pet in the locoregional lymph node staging of non-small cell lung cancer. a compreh... 10751464 - Body ct and oncologic imaging. 3903844 - Controversies in the radiologic diagnosis of pelvic malignancies. 9626214 - Lymph node staging in non-small-cell lung cancer with fdg-pet scan: a prospective study... 1848614 - Mapping intravascular extension of wilms' tumor with magnetic resonance imaging. 19818904 - Magnetic resonance spectroscopy and diffusion tensor imaging in coma survivors: promise... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Nuclear medicine communications Volume: 29 ISSN: 0143-3636 ISO Abbreviation: Nucl Med Commun Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-11-06 Completed Date: 2009-02-24 Revised Date: 2010-09-22 |
Medline Journal Info:
|
Nlm Unique ID: 8201017 Medline TA: Nucl Med Commun Country: England |
Other Details:
|
Languages: eng Pagination: 1046-51 Citation Subset: IM |
Affiliation:
|
Department of Radiolog, Stanford Hospital and Clinics, Stanford, CA, USA. aiagaru@stanford.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Carcinoma / pathology, radiography*, radionuclide imaging* Female Fluorodeoxyglucose F18 / diagnostic use* Humans Middle Aged Neoplasm Metastasis / radiography, radionuclide imaging Ovarian Neoplasms / pathology, radiography*, radionuclide imaging* Positron-Emission Tomography Sensitivity and Specificity Tomography, X-Ray Computed |
| Grant Support | |
ID/Acronym/Agency:
|
P50 CA114747/CA/NCI NIH HHS; P50 CA114747-019005/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
63503-12-8/Fluorodeoxyglucose F18 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 18F-fluoro-2-deoxy-D-glucose standardized uptake value in cavitating non-small-cell lung carcinoma.
Next Document: 13N-NH3: a selective contrast-enhancing tracer for brain tumor.